Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
Autor: | Kentaro Tamaki, Keely May McNamara, Yasuyo Ohi, Saki Nakagawa, Yoshiaki Rai, Minoru Miyashita, Hironobu Sasano, Katsuhiko Ono, Yasuaki Sagara, Takanori Ishida, Hisashi Hirakawa, Noriaki Ohuchi, Fouzia Guestini |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Neoplasm Residual Anthracycline Triple Negative Breast Neoplasms Vimentin Disease-Free Survival Surgical pathology 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Humans PTEN Medicine Breast Mastectomy Triple-negative breast cancer Taxane biology business.industry Middle Aged Prognosis medicine.disease Neoadjuvant Therapy 030104 developmental biology Drug Resistance Neoplasm Tumor progression 030220 oncology & carcinogenesis biology.protein Female Neoplasm Recurrence Local business Follow-Up Studies |
Zdroj: | Breast Cancer Research and Treatment. 173:275-288 |
ISSN: | 1573-7217 0167-6806 |
Popis: | Triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy (NAC) harbor higher risk of relapse, and eventual demise compared to those who achieve pathologic complete response. Therefore, in this study, we assessed a panel of molecules involved in key pathways of drug resistance and tumor progression before and after NAC in TNBC patients, in order to clarify the underlying mechanisms. We studied 148 TNBC Japanese patients treated with anthracycline/taxane-based NAC. KI67, Topoisomerase IIα (TopoIIα), PTEN, p53, Bcl2, vimentin, ABCG2/BCRP1, ABCB1/MDR1, and ABCC1/MRP1 were immunolocalized in surgical pathology materials before and after NAC. The status of vimentin and increasing labeling index (LI) of TopoIIα and KI67 in biopsy specimens were significantly associated with those who responded to NAC treatment. The abundance of p53 (p = 0.003), ABCC1/MRP1 (p = 0.033), ABCB1/MDR1 (p = 0.022), and a loss of PTEN (p |
Databáze: | OpenAIRE |
Externí odkaz: |